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Abstract
Introduction:  Urinary tract infections (UTIs) due to multi-drug resistant Klebsiella  pneumoniae  (K.  pneu-
moniae) strains are increasing worldwide and have become a major public health problem.
Objectives:  The aim of this study was to determine the current and local antimicrobial susceptibility of
urinary K.  pneumoniae  isolated from inpatients and outpatients in a university hospital.
Subjects  and  methods:  A retrospective study was carried out, covering a 3-year period from January 2010
to December 2012. It focused on all the K.  pneumoniae  strains isolated from the urine samples analyzed at
the microbiology laboratory of the Avicenne Teaching Hospital, Marrakech, Morocco, North Africa.
Results:  K.  pneumoniae  represented 22% of all the urinary Enterobacteriaceae  isolated during the study
period. The bacterial resistance rates of K.  pneumoniae  isolates not producing extended-spectrum -
lactamase (ESBL) were as follows: trimethoprim–sulfamethoxazole “T/S” (61%), amoxicillin/clavulanic
acid (51%), ciprofloxacin (32%), gentamicin (21%) and amikacin (11%). ESBL-producing K.  pneumoniae
strains accounted for 25.5% of all the urinary K.  pneumoniae  isolates and showed resistance to T/S (89%),
gentamicin (89%), ciprofloxacin (84%) and amikacin (50%). For the first time in our region, we also noted
the emergence of carbapenem-resistant strains that accounted for 7% of all the urinary ESBL-producing K.
pneumoniae  isolates.
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Conclusions:  Antimicrobial susceptibility testing of urinary K.  pneumoniae  isolates showed a significantly
high resistance to commonly used antimicrobial agents. These data highlight the need for regular surveillance
of microbial resistance to improve infection control and guide the use of antimicrobial agents.
© 2015 Pan African Urological Surgeons’ Association. Production and hosting by Elsevier B.V. All rights reserved.
Introduction
Urinary tract infection (UTI) is a very common reason for consulta-
tion and antibiotic prescription in current practice [1,2]. Excessive
and/or inappropriate use of antibiotics in treating UTIs is respon-
sible for the emergence and spread of multi-drug resistant urinary
bacteria. UTIs caused by multidrug-resistant Klebsiella  pneumo-
niae  isolates are a major public health problem, since the efficacy
of many antimicrobial agents has been restricted, thus reducing the
therapeutic options significantly and making the provision of an
appropriate antimicrobial therapy more challenging. In addition,
multi-drug resistant bacteria are responsible of urinary tract infec-
tions that are hard to treat and this increases the medical costs and
the mortality and morbidity rates [3].
The development of drug-resistant pathogens in patients with seri-
ous infections such as UTIs has generally been ascribed to the
widespread use of antimicrobial agents and the limited availability of
infection prevention and control programs. As a result, it is increas-
ingly common to encounter individuals infected with bacterial
pathogens that are resistant to almost all currently available antibi-
otics. Of particular concern in the healthcare setting is the emergence
of resistant gram-negative pathogens, including ESBL-producing
K.  pneumoniae. While antibiotic resistance was previously noted
mainly in nosocomial UTIs, it is nowadays also frequently observed
in community-acquired UTIs [1,2]
Globally, nonsusceptibility of urinary K.  pneumoniae  to commonly
used oral and parenteral antimicrobial agents is rapidly increasing
and shows large variation temporally and regionally [4]. Empirical
antibiotic therapy is based on epidemiological data that are updated
and adapted geographically [5]. Thus, it is of great importance for
institutions to know the local antibiotic resistance patterns of each
region in order to implement suitable infection control measures and
develop a rational antibiotic policy with local recommendations for
antibiotic use. These surveillance data are also used to assess the
effectiveness of the measures taken and to identify new points for
intervention to control bacterial resistance.
Unlike most developed countries, we unfortunately do not yet
have nationwide surveillance programs for monitoring antimicro-
bial resistance. However, surveillance studies of bacterial resistance
are among the most important measures in terms of controlling the
spread of resistant bacteria. Until now, antimicrobial surveillance
in Morocco has been limited to a few large hospitals. Initial studies
indicated that there has been a significant increase in the preva-
lence of gram-negative bacteria resistant to the commonly used
antimicrobial drugs for the treatment of UTIs. Therefore, the objec-
tive of this regional study was to add valuable data that can assist
the scientific community in the development of a plan for a ratio-
nal use of antimicrobial agents in the treatment of UTIs due to K.
pneumoniae.
Subjects  and  methods
In this retrospective study, all urine samples processed at the micro-
biology laboratory of the Avicenne University Hospital (Marrakech,
Morocco, North Africa) between January 2010 and December 2012
were analyzed. The Avicenne University Hospital serves wide urban
and rural geographic areas in the Marrakech region. During the study
period, urine samples were collected from outpatients and inpatients
hospitalized in different services of our hospital. In cases where mul-
tiple urine cultures from the same patient were positive for the same
organism only the first episode was reviewed and recorded.
Urinary K.  pneumoniae  isolates were identified to the species level
and tested for antimicrobial susceptibility using custom MicroScan
Walkaway dehydrated broth microdilution panels (MicroScan®,
Sacramento, CA, USA) according to the guidelines of the
Antibiogram Committee of the French Society of Microbiology
(CA-SFM) [6]. K.  pneumoniae  strains were classified as ESBL
producers when there was at least a significant reduction (i.e.,
≥  three-fold reduction) in the minimum inhibitory concentration
(MIC) value of the tested antibiotic (i.e. ceftazidime or cefotaxime)
in combination with clavulanic acid as compared to the MIC value
of that antibiotic tested alone.
ESBL production was confirmed by the double-disk synergy test
“DDST”. This phenotypic testing is based on the demonstration of
a synergy image between amoxicillin/clavulanic acid (20/10 mg)
and cefotaxime (30 mg), ceftazidime (30 mg) aztreonam (30 mg)
and cefepime according to the CA-SFM guidelines [6].
The MICs of carbapenems were determined using the agar dilution
method in accordance with the CA-SFM guidelines [6]. The isolates
showing nonsusceptibility to either ertapenem or imipenem (MICs
of ≥2 g/mL) were tested for the production of carbapenemases
using the modified Hodge test (MHT) (Fig. 1).
Results
During the study period, a total of 1472 Enterobacteriaceae  isolates
were obtained from culture specimens of patients diagnosed with
UTI. The Enterobacteriaceae  encountered most frequently were
Escherichia  coli  (63%, n  = 924) and K.  pneumoniae  (22%; n = 321)
(Fig. 2). 263 (82%) strains of K.  pneumoniae  were isolated from
community-acquired UTIs.
The antimicrobial resistance patterns of non-ESBL producing K.
pneumoniae  isolates and ESBL-producing K.  pneumoniae  isolates
are presented in Table 1. During the study period, the percentage of
K.  pneumoniae  strains resistant to third-generation cephalosporins
due to ESBL production increased progressively from 18.2% in
2010 to 29.4% in 2011 and 34.1% in 2012 (Overall 25.5%).
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Figure  1  The MHT performed on a 100 mm Mueller-Hinton agar
plate. (1) K.  pneumoniae, positive result; (2) K.  pneumoniae, negative
result and (3) a clinical K.  pneumoniae  isolate, positive result.
63%
22%
15%
E. coli
K. pneumoniae
Figure  2  Distribution of Enterobacteriaceae  species causing UTIs.
Among the urinary ESBL-producing K.  pneumoniae  isolates
(n  = 82), six strains (7%) showed a cross-resistance to carbapen-
ems, which indicates an emergence of carbapenem-resistant strains
of K.  pneumoniae.
Table  1  Antimicrobial resistance rates among Non-ESBL pro-
ducing K.  pneumoniae  strains and ESBL-producing K.  pneumoniae
strains isolated patients with UTI between January 2010 and
December 2012.
Tested
antibiotic
ESBL producing K.
pneumoniae strains (%)
Non-ESBL producing K.
pneumoniae strains (%)
Aug 100 51
T/S 89 61
Gm 89 21
Cp 84 32
Ak 50 11
Fd 24 13
Fos 6 8
Etp 7 0
Imp 7 0
Aug: amoxicillin/clavulanate; T/S: trimethoprim/sulfamethoxazole;
Gm: gentamicin; Cp: ciprofloxacin; Ak: amikacin; Fd: nitrofurantoin;
Fos: fosfomycin; Etp: ertapenem; Imp: imipenem.
Discussion
UTI is one of the most common infectious diseases [7].
Escherichia  coli  and K.  pneumoniae  have been reported to be the
most common organisms causing UTI. We studied the diversity of
urinary Enterobacteriaceae  isolated at the Avicenne Teaching Hos-
pital (Marrakech, Morocco) from 2010 to 2012. As expected, our
study showed that E.  coli  and K.  pneumoniae  were implicated in
85% of UTIs due to Enterobacteriaceae. This is demonstrated by
the prevalence of these two pathogens in the epidemiology of both
nosocomial and community-acquired UTIs. Although E.  coli  is a
more common cause of UTIs (63%) than K.  pneumoniae  (22%),
the latter creates a dilemma for clinicians because of the multi-drug
resistance expressed by this pathogen [8]. Therefore, it is often a
focus of epidemiologic resistance studies [9].
The prevalence of Klebsiella  species in this study (22%) is almost
the same as the percentages reported in Ethiopia (19–21%) [10] and
Cameroon (18.5%) [11]. In Morocco, urinary K.  pneumoniae  was
isolated in 10% and 28% of the urine samples in the Meknes [12]
and Rabat [13] regions, respectively.
Over the past two decades there has been a wide use of extended
broad-spectrum antimicrobial agents to meet the emerging chal-
lenge of treating UTIs due to gram-negative bacilli. However, these
microbes have developed multiple antimicrobial resistance mecha-
nisms, including enhanced drug efflux, alterations of the drug target
and the production of plasmid-mediated -lactamases [14]. The typ-
ical characteristic of antimicrobial resistance is that there are often
great differences temporally and regionally [4,15].
Antimicrobial susceptibility testing has shown variable levels of
resistance to the tested antibiotics in the treatment of UTIs. More-
over, urinary K.  pneumoniae  isolates have, in general, high rates of
resistance to the commonly used antimicrobial agents. All K.  pneu-
moniae  isolates are naturally resistant to amoxicillin and ampicillin,
due to a constitutively expressed chromosomal class-A -lactamase
[16].
The acquisition of resistance to amoxicillin–clavulanic acid (AMC)
is a global phenomenon showing widely varying occurrence rates. In
the Marrakech region, antimicrobial resistance of urinary K.  pneu-
moniae  isolates to AMC has been reported to be similar to the
resistance rates reported in the Rabat region (Morocco) [13] and
in Algeria (50%) [17]. In Tunisia, nonsusceptibility to AMC was
almost two times lower (23.7%), as reported in the literature [18].
Trimethoprim–sulfamethoxazole (T/S), used extensively in gen-
eral practice, was first introduced as a combination drug that
inhibits bacterial production of folate, causing a bacteriostatic effect.
The frequent use of this antimicrobial agent for the treatment
of community-acquired UTIs has led to higher resistance levels.
In our study, antimicrobial non-susceptibility to T/S (61%) dis-
played by urinary K.  pneumoniae  isolates was similar to that
reported in Algeria (63.2%) [17]. The high rates of resistance to T/S
currently reported in the Marrakech region and in many countries
confirm that this antibiotic should no longer be used as a first-line
treatment of uncomplicated UTIs.
Urinary K.  pneumoniae  isolates show intrinsic sensitivity to flu-
oroquinolones. Ciprofloxacin, an orally well absorbed quinolone,
is commonly used for empirical UTI treatment. Our study showed
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a resistance rate to Ciprofloxacin of 32%. The resistance rate of
urinary K.  pneumoniae  to ciprofloxacin was 33% in the Rabat
region (Morocco) [13]. Because of treatment failure with routine
drugs, fluoroquinolones, such as ciprofloxacin, have been used as
an alternative medication, and this might be responsible for the high
nonsusceptibility to quinolones in urinary K.  pneumoniae  isolates.
Acquired resistance to fluoroquinolones results from a combination
of several mechanisms including a decrease in membrane perme-
ability, overexpression of efflux systems and resistance by mutations
of the topoisomerase in the quinolone-resistance determining region
[19].
With growing resistance of urinary Enterobacteriaceae  to the com-
monly used antimicrobial agents, nitrofurantoin and fosfomycin
have become increasingly important in the treatment of UTIs. They
are known to have less potential for promoting resistance and there-
fore should be used preferentially. In this study, the susceptibility of
K.  pneumoniae  isolates to amikacin, nitrofurantoin and fosfomycin
was the lowest with regard to the non-carbapenem antimicrobial
agents tested.
One major concern associated with urinary Enterobacteriaceae  is
the emergence of ESBL-producing strains. These strains, reported
for the first time in Germany in 1983, confer resistance to
all -lactam antimicrobial agents except cephamycins and car-
bapenems [20]. Over the last two decades, several studies have
reported epidemic outbreaks of ESBL-producing Enterobacteria-
ceae  [21].
Although ESBL production has been reported in a variety of gram-
negative rods, K.  pneumoniae  is one of the organisms most likely
to produce ESBL. The frequency of ESBL production varies sub-
stantially from region to region and is increasing significantly.
In the Marrakech region, the incidence of ESBL-producing uri-
nary Enterobacteriaceae  strains increased from 7% in 2008 to
13% in 2012 [22]. This rapidly rising prevalence of ESBL produc-
tion among Enterobacteriaceae  is the result of selection pressure
due to massive prescription and often misuse of broad-spectrum
antibiotics, including cephalosporins, both in hospitals and the
community. In our study, the prevalence of ESBL-producing K.
pneumoniae  isolates was 25.5% of all clinical urinary K.  pneumo-
niae. Other studies reported a prevalence of 20.2% in Tunisia [18],
of 26% in France [23] and of 20.8% in Spain [24].
The high incidence of ESBL-producing K.  pneumoniae  can mainly
be explained by the spread of these multi-drug resistant strains.
However, only molecular characterization of the ESBL-encoding
genes can prove clone association and relatedness of our ESBL-
producing K.  pneumoniae  isolates. The class A ESBLs, TEM, SHV
and CTX types are the most widespread and clinically relevant
worldwide [25]. In Morocco, ESBL-producing Enterobacteriaceae
have been isolated in different hospitals [12,22], and the ESBL genes
detected in Morocco were blaTEM, blaSHV, blaDHA and blaOXA types
[26].
The genes encoding ESBL enzymes are generally plasmid-
mediated, and additional resistance determinants to aminoglyco-
sides, fluoroquinolones and T/S are often co-transferred on the
same plasmid [27]. Furthermore, many of the ESBL isolates express
cross-resistance between antimicrobial agents. Therefore, they pose
a significant therapeutic challenge to both clinicians and clinical
microbiologists.
Antimicrobial resistance testing showed a very important variety
when comparing ESBL and non-ESBL producing strains of K.  pneu-
moniae. In this study, all ESBL-producing K.  pneumoniae  showed a
high level of resistance (84–89%) to ciprofloxacin, gentamicin and
T/S. For example, the resistance of ESBL-producing K.  pneumoniae
to ciprofloxacin in this study (84%) was similar to the resistance rate
reported in Rabat (capital of Morroco) (85%) [13] and higher than
the one reported in Tunisia (67.5%) [18]. The clinical relevance of
ESBLs has been well documented by numerous published reports
describing clinical failure with the use of commonly used antimicro-
bial agents [28]. Thus, the choice of antimicrobial agents effective
against ESBL-producing organisms is currently very limited.
ESBL production by K.  pneumoniae  isolates is a well-recognized
problem and explains the high resistance rates to commonly used
antimicrobial agents. Due to this steady decrease in susceptibil-
ity to non-carbapenem antibiotics over time, increased carbapenem
consumption has been subsequently reported and speculated to be
associated with an increasing resistance of K.  pneumoniae  isolates to
carbapenems. These antimicrobial agents are considered the treat-
ment of choice for serious infections caused by ESBL-producing
and/or AmpC -lactamase-producing Enterobacteriaceae  because
of their high stability to -lactamase hydrolysis and the relatively
high susceptibility of ESBL producers to carbapenems [29].
For the first time in the region of Marrakech, we have noticed the
emergence of carbapenem-resistant K.  pneumoniae  strains. Among
the urinary ESBL-producing K.  pneumoniae  isolates (n  = 82),
six strains (7%) showed cross-resistance to both ertapenem and
imipenem, which may suggest clonal spread of ESBL-producing
strains highly resistant to group I and group II carbapenems.
Although a high susceptibility to carbapenem has been demon-
strated worldwide, it is noteworthy that since the emergence of
carbapenem-resistant organisms the effectiveness of carbapenem
therapy is speculated to become more limited. Recently, in Rabat
city (Morocco), two isolates of carbapenem-resistant K.  pneumo-
niae  were obtained from the same patient, with one isolate harboring
plasmid-encoded bla-(OXA-48) and the other the bla-(OXA-1) gene
[30]. In addition, Barguigua et al. [26] showed the trends of the emer-
gence of carbapenem-resistant Enterobacteriaceae  in the Moroccan
community setting with carriage of resistance genes with clinical
relevance co-expressed with blaOXA-48 and blaIMP-1.
Avoiding infections reduces the amount of antibiotics to be used
and reduces also the likelihood that resistance will develop during
therapy. Moreover, promoting hand hygiene and the use of antibi-
otics as directed and only when necessary are important measures
to prevent the spread of drug-resistant infections. Besides, there is
an urgent need in Moroccan hospitals to implement prevention and
control programs to reduce the spread of drug-resistant pathogens.
Updates of trends in the use of antimicrobial agents in hospitals
are crucial data for clinical care management and for improving the
habits of antibiotic prescribing.
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